Why Is MicRhoGAM So Hard to Find? [Explained for 2026]

If you've recently had a first-trimester pregnancy loss or early ectopic pregnancy and your provider prescribed MicRhoGAM, you may have run into a frustrating wall: the pharmacy doesn't have it, or it's on backorder. You're not alone. MicRhoGAM — the mini-dose formulation of Rho(D) immune globulin — has been caught in a broader shortage of Rh immune globulin products that began in late 2023 and has continued to disrupt supply into 2026.

This guide explains what MicRhoGAM is, why it's been so hard to find, and what your options are if your pharmacy is out of stock.

What Is MicRhoGAM and Why Is It Important?

MicRhoGAM (Rho(D) immune globulin human, mini-dose) is a biological medication made from human plasma. It contains concentrated IgG antibodies against the Rh(D) antigen — the protein found on red blood cells in Rh-positive individuals. MicRhoGAM is the mini-dose formulation containing 50 mcg (250 IU), designed specifically for early first-trimester events such as miscarriage, induced abortion, or ectopic pregnancy occurring at 12 weeks or less of gestation.

It is manufactured by Kedrion Biopharma Inc. and has been FDA-approved since 1968 under the same biologics license as RhoGAM. Both medications share BLA 103777, making MicRhoGAM one of the longest-standing and most trusted biologics in obstetric care.

Why does it matter? Approximately 15% of pregnant individuals are Rh-negative. If an Rh-negative person experiences fetal blood mixing with their own — even in small quantities during a first-trimester loss — their immune system may develop antibodies against Rh-positive blood cells. Those antibodies can persist and, in a future pregnancy, attack a Rh-positive fetus's red blood cells, potentially causing hemolytic disease of the fetus and newborn (HDFN) — a life-threatening condition. MicRhoGAM, given within 72 hours of the at-risk event, prevents this immune sensitization.

Why Has MicRhoGAM Been So Hard to Find?

The shortage of MicRhoGAM is inseparable from the broader Rho(D) immune globulin (RhIg) shortage that was formally announced in late 2023 and publicly reported by the FDA, the American Society of Health-System Pharmacists (ASHP), and the Association for the Advancement of Blood & Biotherapies (AABB) in early 2024. Several interconnected factors drove the crisis:

1. Anti-D Plasma Is Rare and Difficult to Source

Unlike standard plasma products, Rho(D) immune globulin is made from the plasma of donors who carry high levels of anti-D antibodies — a very specific subset of the donor population. Sourcing enough qualifying anti-D plasma requires specialized donation centers and ongoing recruitment of eligible donors. When demand increases or supply disruptions occur, there is no quick substitute.

2. Manufacturing Deviations at Kedrion Biopharma

Kedrion Biopharma, the sole U.S. manufacturer of both RhoGAM and MicRhoGAM, experienced manufacturing deviations and plant maintenance requirements that compounded the plasma sourcing challenges. Biologics manufacturing requires precise compliance with current Good Manufacturing Practices (cGMP), and any deviation can slow or halt production.

3. Limited Number of U.S. Manufacturers

There are only four FDA-licensed sources of Rho(D) immune globulin in the United States: Kedrion Biopharma (RhoGAM/MicRhoGAM), Grifols Therapeutics (HyperRHO), CSL Behring (Rhophylac), and Kamada (WinRho SDF). When issues arise at one manufacturer, the others cannot simply absorb all of that demand. The WinRho shortage — which affected Kamada — was resolved by August 2024, but the Kedrion shortage affecting MicRhoGAM continued.

4. Retail Pharmacies Are Hit Hardest

Hospitals, OB clinics, and infusion centers often receive biologics through institutional purchasing channels that have somewhat more reliable supply than retail pharmacies. As a result, patients seeking to fill a MicRhoGAM prescription at a neighborhood pharmacy are disproportionately impacted compared to those receiving the injection directly from a hospital or clinic.

What Is the Current Status of the MicRhoGAM Shortage in 2026?

Kedrion Biopharma has taken meaningful steps toward recovery, including bringing manufacturing processes in-house, expanding their KEDPLASMA donation center network, and resuming broader supply. FFF Enterprises, a major distributor, announced that the allocation restriction on RhoGAM had been lifted. However, localized shortages at retail pharmacies continue — availability varies significantly by region and individual pharmacy.

The shortage has also prompted the medical community to explore conservation strategies. The American College of Obstetricians and Gynecologists (ACOG) issued a Practice Advisory recommending that providers confirm neonatal Rh(D) status before administering routine postpartum RhIg and consider non-invasive prenatal testing (NIPT) for fetal RHD genotyping to determine whether a given patient actually needs the injection.

What Are My Options If MicRhoGAM Is Out of Stock?

If your pharmacy is out of MicRhoGAM, don't panic — there are legitimate alternatives your provider can prescribe:

HyperRHO S/D Mini-Dose (Grifols): The direct mini-dose equivalent, also containing 250 IU (50 mcg), for first-trimester events.

Full-dose Rho(D) immune globulin (RhoGAM, HyperRHO S/D Full Dose, Rhophylac, WinRho SDF): Per prescribing information, a full-dose preparation may be used if the mini-dose is unavailable. Ask your provider.

Your provider may also choose to administer the injection directly in-office if they have stock through their institutional supply channels — bypassing the retail pharmacy entirely.

How to Find MicRhoGAM Near You

Because MicRhoGAM availability varies so much from pharmacy to pharmacy, calling around manually is time-consuming — especially when you're managing a pregnancy loss. medfinder calls pharmacies near you to find which ones have MicRhoGAM in stock, then texts you the results — so you don't have to spend time on hold.

You can also check our related guide on how to find MicRhoGAM in stock near you for step-by-step tools and tips.

A Note on Urgency

MicRhoGAM must be administered within 72 hours of the at-risk event. Although the prescribing information notes it should be given as soon as possible (within 3 hours ideally after first-trimester abortion), the 72-hour window applies broadly. Do not delay — if you can't find MicRhoGAM at your regular pharmacy, contact your provider immediately so they can help you locate stock or prescribe an alternative.

See our full guide to MicRhoGAM alternatives if you can't fill your prescription for more on your options.